Claim amendments

1. (originally presented) A compound of Formula I, Formula II, or Formula III:



I



II



III

wherein:

n is an integer of 0 to 4 in Formula I, and is an integer of 0 to 2 in Formula II and Formula III;

X and Y are independently O, S, CH-R^8, or N-R^7 in Formula I and Formula II, and are independently N and C-R^7 in Formula III;

Z is N or C-R^8;

provided that at least one of X, Y, and Z is a non-carbon ring atom;

each R^1 is independently, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), -CF_3, halogen, nitro, -CN, -OR^9, -SR^9, -NR^9R^{10}, -$NR^9(CH_2)_{1\text{-}6}C(=O)OR^{10}$, -$C(=O)R^9$, $C(=O)OR^9$, -$C(=O)NR^9R^{10}$, -$OC(=O)R^9$, -SO_2R^9, -OSO_2R^9, -$SO_2NR^9R^{10}$, -$NR^9SO_2R^{10}$ or -$NR^9C(=O)R^{10}$, wherein R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1\text{-}2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are -$(CH_2)_{4\text{-}6}$- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-$(CH_2)_{1\text{-}6}C(=O)OR$ (where R is hydrogen or lower alkyl) or N-(optionally substituted $C_{1\text{-}2}$ alkyl) group, or in Formula I, n=2 and the two R^1's together constitute =O,

R^2, R^3 and R^8 are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), $-CF_3$, halogen, nitro, -CN, $-OR^9$, $-SR^9$, $-NR^9R^{10}$, $-NR^9(CH_2)_{1-6}C(=O)OR^{10}$, $-C(=O)R^9$, $-(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-OC(=O)R^9$, $-SO_2R^9$, $-OSO_2R^9$, $-SO_2NR^9R^{10}$, $-NR^9SO_2R^{10}$ or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), $N-(CH_2)_{1-6}C(=O)OR$ (where R is hydrogen or lower alkyl) or N-(optionally substituted C_{1-2} alkyl) group,

each R^7 is independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), aryl, substituted aryl, aryl(lower alkyl), substituted aryl(lower alkyl), halo(lower alkyl), $-C(=O)R^9$, $-C(=O)OR^9$; $-C(=O)NR^9R^{10}$, $-SO_2OR^9$, $-SO_2NR^9R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), $N-(CH_2)_{1-6}C(=O)OR$ (where R is hydrogen or lower alkyl) or N-(optionally substituted C_{1-2} alkyl) group,

R^4 and R^5 are independently, hydrogen, lower alkyl optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted aryl(lower alkyl), or, together, are $-(CH_2)_{2-4}-$,

R^6 is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-SO_2R^{11}$, or $-SO_2NR^{11}R^{12}$, where R^{11} and R^{12} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^{11} and R^{12} together are $-(CH_2)_{4-6}-$,

or a pharmaceutically acceptable salt thereof, optionally in the form of a single stereoisomer or mixture of stereoisomers thereof.

2. – 52. (canceled)

53. (new) A compound of formula Ib or formula IIb:



Ib



IIb

where:

n is an integer of 0 to 4 in Formula Ib, and is an integer of 0 to 2 in Formula IIb;

Z is N or C-R^8;

each R^1 is independently optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), -CF_3, halogen, nitro, -CN, -OR^9, -SR^9, -NR^9R^{10}, -$NR^9(CH_2)_{1\text{-}6}C(=O)OR^{10}$, -$C(=O)R^9$, $C(=O)OR^9$, -$C(=O)NR^9R^{10}$, -$OC(=O)R^9$, -SO_2R^9, -OSO_2R^9, -$SO_2NR^9R^{10}$, -$NR^9SO_2R^{10}$ or -$NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1\text{-}2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are -$(CH_2)_{4\text{-}6}$- optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), N-$(CH_2)_{1\text{-}6}C(=O)OR$ (where R is hydrogen or lower alkyl) or N-(optionally substituted $C_{1\text{-}2}$ alkyl) group, or in Formula I, n=2 and the two R^1's together constitute =O,

R^2, R^3 and R^8 are independently hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), -CF_3, halogen, nitro, -CN, -OR^9, -SR^9, -NR^9R^{10}, -$NR^9(CH_2)_{1\text{-}6}C(=O)OR^{10}$, -$C(=O)R^9$, -$(=O)OR^9$, -$C(=O)NR^9R^{10}$, -$OC(=O)R^9$, -$SO_2R^9$, -$OSO_2R^9$, -$SO_2NR^9R^{10}$, -$NR^9SO_2R^{10}$ or -$NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1\text{-}2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl(lower alkyl), aryl(lower alkyl), optionally

substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), $N-(CH_2)_{1-6}C(=O)OR$ (where R is hydrogen or lower alkyl) or N-(optionally substituted C_{1-2} alkyl) group,

R^4 and R^5 are independently hydrogen, lower alkyl optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted aryl(lower alkyl), or, together, are $-(CH_2)_{2-4}-$, and

R^6 is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-SO_2R^{11}$, or $-SO_2NR^{11}R^{12}$, where R^{11} and R^{12} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^{11} and R^{12} together are $-(CH_2)_{4-6}-$,

or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

54. (new) A compound of claim 53 where Z is $C-R^8$.

55. (new) A compound of claim 53 where Z is C-H.

56. (new) A compound of claim 53 where the compound is a compound of Formula Ib,
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

57. (new) A compound of claim 53 where the compound is a compound of Formula IIb,
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

58. (new) A compound of claim 53 where each R^1 is independently, optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, $-OR^9$, $-NR^9R^{10}$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2NR^9R^{10}$, or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), aryl(lower alkyl), optionally substituted aryl, heteroaryl, or heteroaryl(lower alkyl).

59. (new) A compound of claim 53 where n=0.

60. (new) A compound of claim 53 where R^2 is optionally substituted lower alkyl, cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halogen, $-OR^9$, $-NR^9(CH_2)_{1-6}C(=O)OR^{10}$, $-C(=O)OR^9$, $-C(=O)NR^9R^{10}$, $-SO_2NR^9R^{10}$, or $-NR^9C(=O)R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), $N-(CH_2)_{1-6}C(=O)OR$ (where R is hydrogen or lower alkyl) or N-(optionally substituted C_{1-2} alkyl) group.

61. (new) A compound of claim 53 where R^2 is $-NR^9R^{10}$, wherein R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), alkenyl, alkynyl, optionally substituted cycloalkyl, cycloalkyl(lower alkyl), benzyl, optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), $N-(CH_2)_{1-6}C(=O)OR$ (where R is hydrogen or lower alkyl) or N-(optionally substituted C_{1-2} alkyl) group.

62. (new) A compound of claim 53 where R^2 is hydrogen.

63. (new) A compound of claim 53 where the compound is a compound of formula Ib,
where Z is C-H, n =0, and R^2 is hydrogen,
or a pharmaceutically acceptable salt thereof, as a single stereoisomer or mixture of stereoisomers.

64. (new) A compound of claim 53 where R^3 is optionally substituted lower alkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted aryl(lower alkyl), halo(lower alkyl), halogen, $-OR^9$, $-NR^9R^{10}$, $-C(=O)OR^9$, or $-C(=O)NR^9R^{10}$, where R^9 and R^{10} are independently, hydrogen, optionally substituted lower alkyl, lower alkyl-$N(C_{1-2}$ alkyl$)_2$, lower alkyl(optionally substituted heterocycloalkyl), optionally substituted cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or R^9 and R^{10} together are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH, N-(aryl), N-(aryl(lower alkyl)), $N-(CH_2)_{1-6}C(=O)OR$ (where R is hydrogen or lower alkyl) or N-(optionally substituted C_{1-2} alkyl) group.

65. (new) A compound of claim 53 where R^3 is hydrogen.

66. (new) A compound of claim 53 where R^4 and R^5 are independently hydrogen or lower alkyl.

67. (new) A compound of claim 53 where R^6 is hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^{11}R^{12}$, $-SO_2R^{11}$, or $-SO_2NR^{11}R^{12}$, where R^{11} and R^{12} are independently, hydrogen, optionally substituted lower alkyl, cycloalkyl, cycloalkyl(lower alkyl), aryl, heteroaryl, heteroaryl(lower alkyl), or R^{11} and R^{12} together are $-(CH_2)_{4-6}-$.

68. (new) A compound of claim 53 where:

R^6 is 

m is an integer of 0 to 4;

R^{13} is hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkyl(lower alkyl), heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), $-CF_3$, halogen, nitro, $-CN$, $-OR^{15}$, $-SR^{15}$, $-NR^{15}R^{16}$, $-C(=O)R^{15}$, $-C(=O)OR^{15}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)R^{15}$, $-SO_2R^{15}$, $-SO_2NR^{15}R^{16}$, $-NR^{15}SO_2R^{16}$ or $-NR^{15}C(=O)R^{16}$, where R^{15} and R^{16} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, alkynyl, $-CF_3$, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), or, together, are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group, and

each R^{14} is independently optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, $-CF_3$, $-OR^{17}$, $-NR^{17}R^{18}$, $-C(=O)R^{17}$, $-C(=O)OR^{17}$, $-C(=O)NR^{17}R^{18}$, where R^{17} and R^{18} are independently, hydrogen, lower alkyl, alkenyl, alkynyl, $-CF_3$, optionally substituted heterocycloalkyl, cycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, heteroaryl, heteroaryl(lower alkyl), or, together, are $-(CH_2)_{4-6}-$, optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group.

69. (new) A compound of claim 68 where R^{13} is hydrogen, optionally substituted lower alkyl, alkenyl, heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), $-CF_3$, halogen, nitro, -CN, $-OR^{15}$, $-SR^{15}$, $-NR^{15}R^{16}$, $-C(=O)R^{15}$, $-C(=O)OR^{15}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)R^{15}$, $-SO_2R^{15}$, $-SO_2NR^{15}R^{16}$, or $-NR^{15}C(=O)R^{16}$, where R^{15} and R^{16} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl) or, together, are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group.

70. (new) A compound of claim 69 where R^{13} is optionally substituted lower alkyl, alkenyl, heterocycloalkyl, optionally substituted aryl, optionally substituted aryl(lower alkyl), optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl), halo(lower alkyl), $-CF_3$, halogen, nitro, -CN, $-OR^{15}$, $-SR^{15}$, $-NR^{15}R^{16}$, $-C(=O)R^{15}$, $-C(=O)OR^{15}$, $-C(=O)NR^{15}R^{16}$, $-OC(=O)R^{15}$, $-SO_2R^{15}$, $-SO_2NR^{15}R^{16}$, or $-NR^{15}C(=O)R^{16}$, where R^{15} and R^{16} are independently, hydrogen, optionally substituted lower alkyl, alkenyl, cycloalkyl, optionally substituted heterocycloalkyl, cycloalkyl(lower alkyl), optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heteroaryl(lower alkyl) or, together, are $-(CH_2)_{4-6}-$ optionally interrupted by one O, S, NH or N-(C_{1-2} alkyl) group.

71. (new) A compound of claim 70 where R^{13} is independently selected from aryl, substituted aryl, optionally substituted heteroaryl, halogen, $-CF_3$, -CN, $-OR^{15}$, or $-C(=O)OR^{15}$, where R^{15} is hydrogen, lower alkyl or optionally substituted aryl.

72. (new) A compound of claim 68 where each R^{14} is independently selected from optionally substituted lower alkyl, optionally substituted aryl, optionally substituted heteroaryl, hydroxy, halogen, $-CF_3$, $-OR^{17}$ $-NR^{17}R^{18}$, $-C(=O)R^{18}$, $-C(=O)OR^{18}$, and $-C(=O)NR^{17}R^{18}$, where R^{17} and R^{18} are, independently, hydrogen, lower alkyl, alkenyl, or optionally substituted aryl.

73. (new) A compound of claim 68 where each R^{14} is independently selected from halogen, $-CF_3$, $-OR^{17}$, $-C(=O)OR^{17}$, or $-OCH_2C(=O)OR^{17}$, where R^{17} is hydrogen, lower alkyl or optionally substituted aryl.

74. (new) A compound of claim 68 where R^{13} is not hydrogen, and m is an integer of 1 to 2.

75. (new) A compound of claim 74 where m is 1.

76. (new) A compound of claim 68 where R^2 and R^3 are independently selected from hydrogen, lower alkyl, and halogen.

77. (new) A compound of claim 53 that is selected from the group consisting of:
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-chlorophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3,4-dichlorophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-chloro-4-hydroxyphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-({[4-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(4-chlorophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-bromophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-cyanophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(2,4-dichlorophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(4-iodophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-iodophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-({[3-(trifluoromethoxy)phenyl]amino}carbonyl)carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-({[3-(methylethyl)phenyl]amino}carbonyl)carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-methylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(2-iodophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-({[3-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-({[3-(trifluoromethylthio)phenyl]amino}carbonyl)carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(3-ethylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(3-ethoxyphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-({[3-(methylethoxy)phenyl]amino}carbonyl)carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(3-phenylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-({[3-(tert-butyl)phenyl]amino}carbonyl)carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(3-chloro-4-methylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(3-iodo-4-methylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-({[4-methyl-3-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;

2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-({[4-fluoro-3-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-({[3,4-bis(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-({[3,5-bis(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-phenoxyphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-nitrophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3,5-dichlorophenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-acetylphenyl)amino]carbonyl}carboxamide;
methyl 3-{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}benzoate;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-(1H-1,2,3,4-tetrazol-5-yl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(3-ethynylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(3-chloro-2-methylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(5-chloro-2-methylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(5-iodo-2-methylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(5-chloro-2-methoxyphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(3-chloro-2,6-diethylphenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(3-(1,3-thiazol-2-yl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-(2-thienyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-(3-thienyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-(2-furyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(3-(2-pyridyl)phenyl)amino]carbonyl}carboxamide;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-{[(4-(1H-1,2,3,4-tetrazol-5-yl)phenyl)amino]carbonyl}carboxamide;
methyl 5-{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}-2-bromobenzoate;
3-{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}-5-(trifluoromethyl)benzoic acid;
2H,3H-benzo[e]1,4-dioxan-6-yl-N-({[3-hydroxy-5-(trifluoromethyl)phenyl]amino}carbonyl)-carboxamide;
5-{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}-2-bromobenzoic acid;
4-{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}-2-chlorophenyl acetate;
4-{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}-2-chlorophenyl methyl propane-1,3-dioate;

2-[(4-{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}-2-chlorophenyl)oxycarbonyl]-acetic acid;

methyl 2-(4-{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}-2-chlorophenoxy)-acetate;

2-(4-{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}-2-chlorophenoxy)acetic acid;

phenylmethyl 2-(4-{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}-2-chloro-phenoxy)acetate;

4-{[(2H,3H-benzo[e]1,4-dioxan-6-ylcarbonylamino)carbonyl]amino}-2-chlorobenzoic acid;

5-{[(2H,3H-benzo[3,4-e]1,4-dioxin-6-ylcarbonylamino)carbonyl]amino}-2-chlorobenzoic acid;

4-{[(2H,3H-benzo[3,4-e]1,4-dioxin-6-ylcarbonylamino)carbonyl]amino}benzoic acid;

3-{[(2H,3H-benzo[3,4-e]1,4-dioxin-6-ylcarbonylamino)carbonyl]amino}benzoic acid;

2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(2-chloro(4-pyridyl))amino]carbonyl}carboxamide;

2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(6-chloro-4-methylpyrimidin-2-yl)amino]carbonyl}carboxamide;

2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-({[5-(trifluoromethyl)(1,3,4-thiadiazol-2-yl)]amino}carbonyl)-carboxamide;

2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(3-chlorophenyl)(methoxymethyl)amino]carbonyl}-N-(methoxymethyl)carboxamide; and

2H,3H-benzo[3,4-e]1,4-dioxin-6-yl-N-{[(3-chlorophenyl)amino]carbonyl}-N-[(2-methoxy-ethoxy)methyl]carboxamide;

and the pharmaceutically acceptable salts thereof, as single stereoisomers or mixtures of stereoisomers.

78. (new) A pharmaceutical composition comprising:

(a) a therapeutically effective amount of a compound of claim 53; and

(b) a pharmaceutically acceptable excipient.

79. (new) The pharmaceutical composition of claim 78 further comprising an anti-inflammatory drug, cytokine, or immunomodulator.

80. (new) A method of treating an allergic, inflammatory, or autoimmune disease in a mammal, comprising administration to the mammal of a therapeutically effective amount of a compound of claim 53.

81. (new) The method of claim 80, where the disease is asthma.

82. (new) The method of claim 80, where the disease is pulmonary fibrosis.

83. (new) The method of claim 80, where the disease is diabetic nephropathy.

84. (new) The method of claim 80, where the disease is rheumatoid arthritis.

85. (new) The method of claim 80, where the disease is restenosis.

86. (new) The method of claim 80, where the disease is pancreatitis.

87. (new) The method of claim 80, where the disease is glomerulonephritis.

88. (new) The method of claim 80, where the disease is atherosclerosis.

89. (new) The method of claim 80, where the disease is inflammatory bowel disease.

90. (new) The method of claim 80, where the disease is Crohn's disease.

91. (new) The method of claim 80, where the disease is transplant rejection.

92. (new) The method of claim 80, where the disease is associated with lymphocyte and/or monocyte accumulation.

93. (new) The method of claim 80, where the compound is administered in combination with an anti-inflammatory drug, cytokine, or immunomodulator.

94. (new) A method of inhibiting leukocyte migration in a mammal, comprising administration to the mammal of a therapeutically effective dose of a compound of claim 53.